Harbor Capital Advisors Inc. Has $198,000 Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)

Harbor Capital Advisors Inc. trimmed its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 29.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 25,607 shares of the biotechnology company’s stock after selling 10,475 shares during the period. Harbor Capital Advisors Inc. owned about 0.05% of REGENXBIO worth $198,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently made changes to their positions in the company. Barclays PLC lifted its position in REGENXBIO by 141.3% in the 3rd quarter. Barclays PLC now owns 116,024 shares of the biotechnology company’s stock valued at $1,217,000 after acquiring an additional 67,948 shares in the last quarter. Integral Health Asset Management LLC raised its stake in shares of REGENXBIO by 25.0% in the second quarter. Integral Health Asset Management LLC now owns 950,000 shares of the biotechnology company’s stock worth $11,115,000 after purchasing an additional 190,000 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of REGENXBIO by 602.9% in the third quarter. BNP Paribas Financial Markets now owns 20,441 shares of the biotechnology company’s stock worth $214,000 after purchasing an additional 17,533 shares during the last quarter. Squarepoint Ops LLC lifted its holdings in shares of REGENXBIO by 630.9% in the second quarter. Squarepoint Ops LLC now owns 146,259 shares of the biotechnology company’s stock valued at $1,711,000 after purchasing an additional 126,249 shares in the last quarter. Finally, FMR LLC boosted its position in shares of REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock valued at $28,000 after buying an additional 1,656 shares during the last quarter. 88.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several brokerages have weighed in on RGNX. Chardan Capital restated a “buy” rating and set a $52.00 price objective on shares of REGENXBIO in a research note on Wednesday, November 20th. StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, September 20th. Morgan Stanley reaffirmed an “overweight” rating and issued a $22.00 price objective on shares of REGENXBIO in a research report on Friday, November 15th. Raymond James reissued an “outperform” rating and set a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Finally, HC Wainwright reduced their target price on REGENXBIO from $40.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, November 21st. Two analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $35.27.

REGENXBIO Trading Up 1.4 %

Shares of NASDAQ RGNX opened at $7.05 on Wednesday. The firm has a market cap of $349.29 million, a price-to-earnings ratio of -1.40 and a beta of 1.28. The stock has a fifty day simple moving average of $8.95 and a two-hundred day simple moving average of $10.59. REGENXBIO Inc. has a 1-year low of $6.56 and a 1-year high of $28.80.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.